Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 5Rhabdomyosarcoma 4Osteosarcoma 3Carcinoma, Non-Small-Cell Lung 3Sarcoma, Synovial 2Prostatic Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Liposarcoma 2Hemangiosarcoma 2Fibrosarcoma 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Adrenocortical Carcinoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Uveal Melanoma 1Unspecified Childhood Solid Tumor, Protocol Specific 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Retinoblastoma 1Pinealoma 1Paraganglioma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms 1Mesothelioma, Malignant 1Malignant mesenchymal tumor 1

Interventions

Radiotherapy 3Ifosfamide 3Doxorubicin 3Vincristine 2Neoadjuvant Therapy 2Etoposide 2Epirubicin 2Dactinomycin 2Cyclophosphamide 2Chemotherapy, Adjuvant 2Carboplatin 2romidepsin 1cixutumumab 1Temozolomide 1Sorafenib 1Peripheral Blood Stem Cell Transplantation 1Molecular Diagnostic Techniques 1Microarray Analysis 1Magnetic Resonance Spectroscopy 1Filgrastim 1Brachytherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hemangiopericytoma, Malignant × cixutumumab × Clear all
NCT00720174 2016-05-17

Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
Sarcoma

Malignant mesenchymal tumor, Hemangiopericytoma, Malignant, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡